菜单

Perspectives

Developing Next-Gen Cell Lines Using Targeted Integration
Jan. 04, 2026
Developing Next-Gen Cell Lines Using Targeted Integration

In a recent feature on BioPharm International, WuXi Biologics’ Cell Line Development team showcased how its proprietary WuXia™ TrueSite platform is transforming CHO cell line development. By leveraging targeted integration technology, WuXia™ TrueSite delivers predictable productivity, superior stability, and consistent product quality.

 

The platform routinely achieves pool titers around 6 g/L and lead clone productivity near 8 g/L, with optimization pushing yields beyond 10 g/L. Its robust stability—maintaining expression across 60 population doublings—and quality consistency between pools and clones support accelerated timelines, including a targeted six-month IND submission. This approach eliminates traditional bottlenecks, streamlines CMC workflows, and empowers developers to move from R&D to commercialization faster and with reduced technical risk.

 

Learn more about the article: Developing Next-Gen Cell Lines Using Targeted Integration